Research graph
References from Adjuvant therapy in chromophobe renal cell carcinoma: current evidence and unmet needs. Local targets link to admitted publications; unresolved targets remain external evidence.
Real world data on treatment of chromophobe renal cell carcinoma
10.1200/jco.2024.42.4_suppl.409 · 2024 · External reference
Recommendations for the management of rare kidney cancers
10.1016/j.eururo.2017.06.040 · 2017 · External reference
Prognostic value of histologic subtypes in renal cell carcinoma: a multicenter experience
10.1200/jco.2005.07.055 · 2005 · External reference
Adjuvant therapy in renal cell carcinoma (RCC): progress, at last
10.21037/tcr-23-2247 · 2024 · External reference
Local and distant recurrence of the chromophobe renal cell carcinoma
2020 · External reference
Pattern, timing and predictors of recurrence after surgical resection of chromophobe renal cell carcinoma
10.1007/s00345-021-03683-9 · 2021 · External reference
Chromophobe renal cell carcinoma: a clinicopathologic study of 203 tumors in 200 patients with primary resection at a single institution
10.1097/pas.0b013e31821a455d · 2011 · External reference
Sarcomatoid features and lymph node-positive disease in chromophobe renal cell carcinoma
10.1016/j.urolonc.2021.06.016 · 2021 · External reference
Adjuvant therapy options in renal cell carcinoma— targeting the metastatic cascade
10.1038/s41585-022-00666-2 · 2023 · External reference
Adjuvant Sunitinib in high-risk renal-cell carcinoma after nephrectomy
10.1056/nejmoa1611406 · 2016 · External reference
Adjuvant Pazopanib versus placebo after nephrectomy in patients with localized or locally advanced renal cell carcinoma: Final overall survival analysis of the phase 3 PROTECT trial
10.1016/j.eururo.2020.12.029 · 2021 · External reference
Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial
10.1016/s0140-6736(16)00559-6 · 2016 · External reference
Adjuvant Sorafenib for renal cell carcinoma at intermediate or high risk of relapse: Results from the SORCE randomized phase III intergroup trial
10.1200/jco.20.01800 · 2020 · External reference
Axitinib versus placebo as an adjuvant treatment of renal cell carcinoma: results from the phase III, randomized ATLAS trial
10.1093/annonc/mdy454 · 2018 · External reference
Perioperative nivolumab versus observation in patients with renal cell carcinoma undergoing nephrectomy (PROSPER ECOG-ACRIN EA8143): an open-label, randomised, phase 3 study
10.1016/s1470-2045(24)00211-0 · 2024 · External reference
Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trial
10.1016/s0140-6736(22)02574-0 · 2023 · External reference
Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trial
10.1016/s0140-6736(22)01658-0 · 2022 · External reference
Overall survival with adjuvant pembrolizumab in renal-cell carcinoma
10.1056/nejmoa2312695 · 2024 · External reference
Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
10.1016/s1470-2045(22)00487-9 · 2022 · External reference
Adjuvant pembrolizumab plus belzutifan versus pembrolizumab for clear cell renal cell carcinoma (ccRCC): The randomized phase 3 LITESPARK-022 study
10.1200/jco.2026.44.7_suppl.lba418 · 2026 · External reference
RAMPART: A phase III multi-arm multi-stage trial of adjuvant checkpoint inhibitors in patients with resected primary renal cell carcinoma (RCC) at high or intermediate risk of relapse
10.1016/j.cct.2021.106482 · 2021 · External reference
Molecular characterization of chromophobe renal cell carcinoma reveals mTOR pathway alterations in patients with poor outcome
10.1038/s41379-020-0607-z · 2020 · External reference
Mutations in a novel gene lead to kidney tumors, lung wall defects, and benign tumors of the hair follicle in patients with the Birt-Hogg-Dubé syndrome
10.1016/s1535-6108(02)00104-6 · 2002 · External reference
Homozygous loss of BHD causes early embryonic lethality and kidney tumor development with activation of mTORC1 and mTORC2
10.1073/pnas.0908853106 · 2009 · External reference
Chromophobe renal cell carcinoma with prolonged response to targeted therapy: a case report
10.1186/1752-1947-6-115 · 2012 · External reference
The somatic genomic landscape of chromophobe renal cell carcinoma
10.1016/j.ccr.2014.07.014 · 2014 · External reference
Adjuvant everolimus after surgery for renal cell carcinoma (EVEREST): a double-blind, placebo-controlled, randomised, phase 3 trial
10.1016/s0140-6736(23)00913-3 · 2023 · External reference
Adjuvant everolimus in non–clear cell renal cell carcinoma: A secondary analysis of a randomized clinical trial
10.1001/jamanetworkopen.2024.25288 · 2024 · External reference
Phase II trial of everolimus for the treatment of nonclear-cell renal cell carcinoma
10.1093/annonc/mds582 · 2013 · External reference
Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma
10.1186/s40425-018-0319-9 · 2018 · External reference
Open-label, single-arm, phase II study of pembrolizumab monotherapy as first-line therapy in patients with advanced non-clear cell renal cell carcinoma
10.1200/jco.20.02365 · 2021 · External reference
A single-arm, multicenter, phase 2 study of lenvatinib plus everolimus in patients with advanced non-clear cell renal cell carcinoma
10.1016/j.eururo.2021.03.015 · 2021 · External reference
Phase II trial and correlative genomic analysis of everolimus plus bevacizumab in advanced non–clear cell renal cell carcinoma
10.1200/jco.2016.67.9084 · 2016 · External reference
Phase II trial of cabozantinib plus nivolumab in patients with non–clear-cell renal cell carcinoma and genomic correlates
10.1200/jco.21.01944 · 2022 · External reference
Current status of adjuvant immunotherapy and relapse management in renal cell carcinoma: Insights from a European delphi study
10.1016/j.ejca.2025.115569 · 2025 · External reference
Clinical review on the management of metastatic renal cell carcinoma
10.1200/op.21.00419 · 2022 · External reference
Unresolved reference
2021 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
